Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Trial Profile

Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Jun 2018 to 31 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results assessing safety data from AFFIRM,PREVAIL,TERRAIN,STRIVE trials (n=3681) presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top